Rather, this study supports the increasing literature that suggests CSF NPTX2 as a surrogate marker of underlying interneuronal circuit dysfunction in sporadic and, now genetic, forms of AD even at the preclinical stage. This evidence concerns the gene NPTX2 and Alzheimer disease.